BridgeBio Pharma to Present Data from Encaleret Trial
BridgeBio Pharma will present additional evidence from the Phase 3 CALIBRATE trial of encaleret in ADH1 at the ASBMR 2026 Annual Meeting.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
BridgeBio Pharma will present additional evidence from the Phase 3 CALIBRATE trial of encaleret in ADH1 at the ASBMR 2026 Annual Meeting.